|
Patients aged <80 years
|
Patients aged ≥80 years
|
All patients
|
---|
|
Full model
|
Full model
|
Full model
|
---|
|
HR (95% CI)
|
HR (95% CI)
|
HR (95% CI)
|
---|
Antithrombotic drugs
| | | |
Antiplatelets vs. no treatment
|
0.86 (0.43-1.72)
|
0.47 (0.26-0.87)
|
0.70 (0.45-1.09)
|
Anticoagulants vs. no treatment
|
0.40 (0.17-0.91)
|
0.49 (0.24-1.00)
|
0.45 (0.26-0.77)
|
Anticoagulants vs. antiplatelets
|
0.44 (0.25-0.78)
|
1.02 (0.60-1.73)
|
0.62 (0.42-0.92)
|
Digitalis
|
0.81 (0.54-1.23)
|
0.90 (0.60-1.35)
|
0.83 (0.62-1.11)
|
Loop diuretics
|
2.42 (1.36-4.33)
|
1.02 (0.60-1.73)
|
1.55 (1.06-2.28)
|
Thiazides
|
0.98 (0.59-1.63)
|
0.89 (0.55-1.44)
|
0.93 (0.66-1.32)
|
Aldosterone antagonists
|
1.20 (0.76-1.88)
|
1.22 (0.79-1.88)
|
1.29 (0.94-1.77)
|
Beta blockers
|
0.62 (0.40-0.97)
|
0.73 (0.49-1.10)
|
0.67 (0.49-0.90)
|
RAS-blocking agents
|
1.08 (0.65-1.78)
|
1.23 (0.79-1.93)
|
1.16 (0.83-1.62)
|
Calcium receptor-blocking agents
|
1.06 (0.69-1.63)
|
1.20 (0.77-1.87)
|
1.10 (0.81-1.49)
|
Statins
|
0.45 (0.29-0.71)
|
0.77 (0.47-1.26)
|
0.56 (0.40-0.78)
|
- Full model is adjusted for a propensity score comprising sex, age group, co-morbidities, educational level, marital status and for all pharmacotherapies. HRs and 95% CIs are shown. Statistically significant HRs are highlighted in bold.